Publications by authors named "N Houhou-Fidouh"
Toxoplasmosis is a ubiquitous parasitic infection caused by Toxoplasma gondii (Tg). In immunocompetent people, the infection may be asymptomatic with the induction of an immune response that may prevent reinfection or transmission to the fetus in immune pregnant woman. In immunocompromised persons or seronegative pregnant woman with a primary infection during pregnancy, the infection may result in the loss of life, sight, cognition, and motor function in the immune-compromised person or immunologically immature fetus.
View Article and Find Full Text PDFIn May 2022, several countries reported mpox cases from patients without history of traveling to endemic areas. France was one of the most affected European countries by this outbreak. In this study, the clinical characteristics of mpox cases in France were described, and the genetic diversity of the virus was studied.
View Article and Find Full Text PDFArticle Synopsis
- STAT2 is a crucial transcription factor activated by specific interferons, and 23 patients with mutations leading to a complete loss of STAT2 function were studied.
- These patients suffered from severe immune issues, including disastrous reactions to live vaccines and deadly viral infections like critical influenza and COVID-19 pneumonia.
- The study emphasizes the danger of AR complete STAT2 deficiency, as it causes significant inflammation and high mortality rates, especially in young children, due to unregulated viral responses.
Objectives: A global outbreak of monkeypox virus infections in human beings has been described since April 2022. The objectives of this study were to describe the clinical characteristics and complications of patients with a monkeypox infection.
Methods: All consecutive patients with a polymerase chain reaction (PCR)-confirmed monkeypox infection seen in a French referral centre were included.
Objective: Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic hearing and neurological deficits. The aim of our study was to evaluate the efficacy and safety of valacyclovir (VCV) treatment in preventing CMV transmission to the fetus after maternal primary infection.
Methods: This was a retrospective, multicenter study evaluating the rate of maternal-fetal CMV transmission in pregnancies with maternal primary CMV infection treated with VCV at a dosage of 8 g per day (VCV group) compared with a control group of untreated women.